Progress on the drugs for regulating high-density lipoprotein
- VernacularTitle:调节高密度脂蛋白药物研究进展
- Author:
Qinkai LI
;
Weidong YIN
- Publication Type:Journal Article
- Keywords:
high-density lipoprotein(HDL);
atherosclerosis(AS);
coronary atherosclerosis disease(CAD);
apolipoprotein;
cholesterol ester transfer protein(CETP);
peroxisomal proliferator-activated receptor(PPAR);
lipoprotein lipase(LPL)9129
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2004;0(08):-
- CountryChina
- Language:Chinese
-
Abstract:
Atherosclerosis (AS) is pathologically important basis of many kinds of coronary atherosclerosis disease (CAD). It can be substantially protected by raising high-density lipoprotein (HDL).In view of mechanism, drugs for raising HDL include: cholesterol ester transfer protein inhibitors, peroxisomal proliferator-activated receptor agonists, liver X-activated receptor agonists, farnesoid X receptor antagonists or agonists, lipoprotein lipase activators, niacin, and phenytoin and lecin : cholesterol acyltransferase activators, etc. This review aimed to the progress of drugs for regulating high-density lipoprotein and their mechanism, in view of clinical and preclinical aspects.
